Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Knight Therapeutics Inc.
  6. News
  7. Summary
    GUD   CA4990531069

KNIGHT THERAPEUTICS INC.

(GUD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Knight Therapeutics : Says Health Canada Approves Neratinib for Treatment of HER2-Positive Breast Cancer

07/06/2021 | 08:52am EDT


ę MT Newswires 2021
All news about KNIGHT THERAPEUTICS INC.
08/16KNIGHT THERAPEUTICS : Reports Second Quarter 2021
AQ
08/16NORTH AMERICAN MORNING BRIEFING : Weak Chinese -3-
DJ
08/13KNIGHT THERAPEUTICS : Posts Q2 EPS of C$0.23; Revenue Reaches Record C$65.8 Mill..
MT
08/13Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on..
CI
08/13KNIGHT THERAPEUTICS : Earnings Flash (GUD.TO) KNIGHT THERAPEUTICS Posts Q2 EPS B..
MT
08/13KNIGHT THERAPEUTICS : Earnings Flash (GUD.TO) KNIGHT THERAPEUTICS Reports Q2 Rev..
MT
08/13NORTH AMERICAN MORNING BRIEFING : Blockbuster -3-
DJ
08/06Notice of Knight Therapeutics' Second Quarter 2021 Results Conference Call
GL
07/13Knight Therapeutics Inc.'s Equity Buyback announced on July 10, 2020, has exp..
CI
07/12UPDATE : Knight Therapeutics Up 3% as Launches Normal Course Issuer Bid
MT
More news
Financials
Sales 2021 237 M 185 M 185 M
Net income 2021 33,5 M 26,1 M 26,1 M
Net Debt 2021 - - -
P/E ratio 2021 18,6x
Yield 2021 -
Capitalization 640 M 500 M 500 M
Capi. / Sales 2021 2,70x
Capi. / Sales 2022 2,24x
Nbr of Employees 679
Free-Float 81,4%
Chart KNIGHT THERAPEUTICS INC.
Duration : Period :
Knight Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KNIGHT THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 5,23 CAD
Average target price 7,66 CAD
Spread / Average Target 46,4%
EPS Revisions
Managers and Directors
Samira Sakhia President, Chief Executive Officer & Director
Utchanah Arvind Chief Financial Officer
Jonathan Ross Goodman Executive Chairman
James Charles Gale Lead Independent Director
Robert N. Lande Independent Director
Sector and Competitors